Corcept Therapeutics submitted a New Drug Application (NDA) to the FDA for relacorilant as a treatment for hypercortisolism on December 30, 2024. The analyst anticipates that, following a standard ...

The following is a summary of "Impact Of Hypercortisolism Beyond Metabolic Syndrome On Left Ventricular Performance: A Myocardial Work Analysis,” published in the March 2025 issue of Cardiovascular ...

The company’s sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome or endogenous ...